Half-Year 2022 Financial and Clinical Trials Update

2022 sales outlook confirmed Sales drivers¹ Pharma: New products with accelerating growth Diagnostics: Base business with strong growth AHR² biosimilars: Roughly CHF -2.5 bn sales erosion COVID-19 sales for Diagnostics and Pharma around CHF 5 bn 1 At Constant Exchange Rates (CER); 2 AHR=Avastin, Herceptin, Rituxan/MabThera 7 . • . Guidance stable to low-single digit group sales growth Group sales to grow high-single digit if COVID-19 sales and AHR get excluded Guidance based on a scenario with significantly reduced COVID-19 impact in H2 Roche 15

View entire presentation